Real-world Evidence of Axicabtagene Ciloleucel for the Treatment of ...
Axicabtagene ciloleucel (axi-cel) shows durable response in real-world settings for relapsed or refractory large B-cell lymphoma, including ZUMA-1 ineligible patients. Elderly patients had favorable outcomes despite higher CRS and ICANS rates. Patient selection should consider comorbidities and risk-to-benefit ratio.
Reference News
Real-world Evidence of Axicabtagene Ciloleucel for the Treatment of ...
Axicabtagene ciloleucel (axi-cel) shows durable response in real-world settings for relapsed or refractory large B-cell lymphoma, including ZUMA-1 ineligible patients. Elderly patients had favorable outcomes despite higher CRS and ICANS rates. Patient selection should consider comorbidities and risk-to-benefit ratio.